Search

Author/Creator Gravalos, C.

1. 2128 Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD). (September 2015)

Authors:
Abad, A.; Massuti, B.; Gravalos, C.; Escudero, P; Guillen-Ponce, C.; Manzano, J.L.; Ortiz, M.J.; Safont, M.J.; Gallego, J.; Sastre, J.; Pericay, C.; Duenas, R.; Rivera, F.; Losa, F.; Valladares-Ayerbes, M.; Gonzalez, E.; Robles, L.; Aranda, E.; Carrato, A.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S374
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 2151 Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC). (September 2015)

Authors:
Shinozaki, E.; Laurent, S.; Gravalos, C.; Benavides, M.; Munoz, F. Longo; Mizuguchi, H.; Wahba, M.; Ychou, M.; Ciardiello, F.; Siena, S.; Yamaguchi, K.; Muro, K.; Denda, T.; Tsuji, Y; Loehrer, P; Lenz, H.J.; Tebbutt, N.; Mayer, R.J.; Van Cutsem, E.; Ohtsu, A.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S383
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search